



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 37/56, C12N 11/00, 9/88 // 9/96	A1	(11) International Publication Number: WO 95/00171 (43) International Publication Date: 5 January 1995 (05.01.95)
(21) International Application Number: PCT/DK94/00224 (22) International Filing Date: 9 June 1994 (09.06.94) (30) Priority Data: 0755/93 25 June 1993 (25.06.93) DK (71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK). (72) Inventors; and (75) Inventors/Applicants (for US only): EIGTVED, Peter [DK/DK]; Parcelvej 42A, DK-2840 Holte (DK). CLAUSEN, Ib, Groth [DK/DK]; Fyrrestien 6, DK-3400 Hillerød (DK). (74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsvaerd (DK).		(81) Designated States: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: A STABILISED PHENYLALANINE AMMONIA LYASE (57) Abstract <p>This invention relates to stabilisation of phenylalanine ammonia lyase against proteolytic degradation by chemical modification, e.g. with crosslinking agents, or by genetic modification, a phenylalanine ammonia lyase variant, a method of preparing the variant and a pharmaceutical composition containing phenylalanine ammonia lyase.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

A STABILISED PHENYLALANINE AMMONIA LYASE

FIELD OF INVENTION

The present invention relates to a stabilised phenylalanine ammonia lyase, a phenylalanine ammonia lyase variant, a method of preparing the variant and a pharmaceutical composition containing phenylalanine ammonia lyase.

BACKGROUND OF THE INVENTION

Hyperphenylalaninemia, which may be defined as a plasma level of phenylalanine of more than 120 $\mu\text{mol/l}$, is a hereditary disease caused by a deficiency in the hepatic enzyme phenylalanine hydroxylase or (in rare cases) its cofactor tetrahydropterin or the cofactor-regenerating enzyme dihydropterin reductase. The disease exists in different forms, phenylketonuria (PKU) which, if the patient is on a normal diet, has plasma phenylalanine levels of more than 1200 $\mu\text{mol/l}$, and non-PKU hyperphenylalaninemia which has lower levels of plasma phenylalanine.

In normal subjects, phenylalanine hydroxylase converts phenylalanine to tyrosine. Highly increased plasma levels of phenylalanine ($>600 \mu\text{mol/L}$) result in mental retardation. The effect appears to be ascribable to phenylalanine itself (not any metabolites thereof), but the mechanism is not yet fully understood. In most industrialised countries, newborn children are routinely screened for hyperphenylalaninemia. The negative effects of increased plasma levels of phenylalanine may, to a large extent, be prevented if a low-phenylalanine diet is introduced shortly after birth and continued well into adolescence. The aim is to obtain plasma phenylalanine levels of 180-425 $\mu\text{mol/l}$. After adolescence, the low-phenylalanine regimen may be somewhat relaxed, although phenylalanine-free products are still a significant component of the diet. Pregnant hyperphenylalaninemic patients are required to go back on a strict low-phenylalanine diet in order to avoid the effects of excessive intrauterine phenylalanine, i.e. congeni-

tal malformation, microcephaly and mental retardation of the fetus.

The strict low-phenylalanine regimen is tiresome for the patients and their families, and is very difficult to enforce beyond childhood. Enzyme therapy to make up for the phenylalanine hydroxylase deficiency would therefore provide a great improvement in the treatment of hyperphenylalaninemia. Unlike phenylalanine hydroxylase, another phenylalanine-degrading enzyme, phenylalanine ammonia lyase, requires no cofactors to be active. Phenylalanine ammonia lyase converts phenylalanine to trans-cinnamic acid which, via coenzyme A, is converted to benzoic acid which reacts with glycine and is then excreted via urine primarily as hippurate. The enzyme may, for instance, be obtained from the yeast Rhodotorula glutinis (also known as Rhodospiridium toruloides). It has previously been suggested to use phenylalanine ammonia lyase for treatment of hyperphenylalaninemia, vide for instance, J.A. Hoskins et al., Lancet, February 23, 1980, pp. 392-394. Proteolytic degradation of the enzyme in the gastrointestinal tract has been recognized, e.g. by H.J. Gilbert and G.W. Jack, Biochem. J. 199, 1981, pp. 715-723. Various attempts to overcome this problem have been published. Thus, L. Bourget and T.M.S. Chang, Biochim. Biophys. Acta 883, 1986, pp. 432-438, propose micro-encapsulation of the enzyme in "artificial cells" composed of phenylalanine ammonia lyase mixed with hemoglobin and enclosed in microspheres covered by a cellulose nitrate membrane. H. J. Gilbert and M. Tully, Biochem. Biophys. Res. Comm. 131(2), 1985, pp. 557-563 propose using permeabilised cells of Rhodospiridium toruloides containing the enzyme. However, both of these approaches may have drawbacks such as low specific phenylalanine ammonia lyase activity of the final preparation or high cost due to processing or formulation.

DESCRIPTION OF THE INVENTION

The object of the present invention is to overcome the drawbacks of the previously suggested methods of stabilising phenylalanine ammonia lyase.

5 Accordingly, the present invention relates to an enzyme preparation comprising phenylalanine ammonia lyase (PAL) stabilised against proteolytic degradation by chemical or genetic modification.

In a preferred embodiment of the enzyme preparation
10 of the invention, the PAL is chemically stabilised by treatment with a cross-linking agent. For the present purpose, it is assumed that the cross-linking agent reinforces the conformation of PAL and makes it less accessible to proteolytic enzymes in the gastrointestinal tract by reticulating the molecule
15 (intramolecular cross-links) to form a brace. Intermolecular cross-linking to another molecule (typically another protein) may also be advantageous to form a conjugate in which the enzyme is protected from the action of proteases. A further description of chemical cross-linking of proteins may be found
20 in, e.g., S.S. Wong and L.-J. C. Wong, Enzyme Microb. Technol. 14, 1992, pp. 866-873. Preferred cross-linking reagents are selected from aldehydes, isocyanates, isothiocyanates, anhydrides and azides. Particularly preferred cross-linking agents are bifunctional reagents, i.e. compounds with two
25 reactive groups. Examples of such reagents are pharmaceutically acceptable carbodiimides, isoxazolium derivatives, chloroformates, carbonyldiimidazole, bis-imidoesters, bis-succinimidyl derivatives, di-isocyanates, di-isothiocyanates, di-sulfonyl halides, bis-nitrophenyl esters, dialdehydes, dia-
30 cylazides, bis-maleimides, bis-haloacetyl derivatives, di-alkyl halides and bis-oxiranes. A currently preferred cross-linking agent for the present purpose is glutaraldehyde. This compound is inexpensive, readily available and approved for a number of food-related enzyme applications. It yields a product with good
35 mechanical properties and good recovery of the enzymatic activity.

The PAL is an intracellular enzyme and may as such be present in whole cells or permeabilised cells, or it may be present in a cell homogenate. The PAL may also be cell-free, affording a preparation which is not diluted with enzymatically inactive cell material and consequently is enriched in enzymatic activity. In the enzyme preparation of the invention, PAL preferably constitutes at least 25%, in particular at least 50%, of the enzyme protein in the preparation. In a specific embodiment, the PAL is in crystalline (i.e. substantially pure) form which may be advantageous for formulation, dosage or approval purposes.

The cross-linking reaction may be carried out at room temperature or at lower temperatures. Higher reaction temperatures during cross-linking may inactivate the enzyme. For effective cross-linking, the reaction time may vary from a few minutes to several hours. The pH of the cross-linking medium should be one which ensures reactivity of the cross-linking agent concomitantly with enzyme activity. When glutaraldehyde is used as the cross-linking agent, a pH of about 6-10 will be the most appropriate. In case of cell-free or crystalline PAL, it may be advantageous to include an auxiliary substance such as a polyamine in the cross-linking reaction.

In another aspect, the present invention relates to a PAL variant stabilised against proteolytic degradation, wherein one or more amino acid residues susceptible to proteolytic cleavage are substituted by one or more amino acid residues less susceptible to proteolytic cleavage.

In the present description and claims, the following abbreviations are used:

Amino Acids:

A	=	Ala	=	Alanine
V	=	Val	=	Valine
L	=	Leu	=	Leucine
5 I	=	Ile	=	Isoleucine
P	=	Pro	=	Proline
F	=	Phe	=	Phenylalanine
W	=	Trp	=	Tryptophan
M	=	Met	=	Methionine
10 G	=	Gly	=	Glycine
S	=	Ser	=	Serine
T	=	Thr	=	Threonine
C	=	Cys	=	Cysteine
Y	=	Tyr	=	Tyrosine
15 N	=	Asn	=	Asparagine
Q	=	Gln	=	Glutamine
D	=	Asp	=	Aspartic Acid
E	=	Glu	=	Glutamic Acid
K	=	Lys	=	Lysine
20 R	=	Arg	=	Arginine
H	=	His	=	Histidine

In describing PAL variants according to the invention, the following nomenclature is used for ease of reference:
Original amino acid(s):position(s):substituted amino acid(s)

25 According to this nomenclature, for instance the substitution of alanine for phenylalanine in position 629 is shown as:

F629A

According to the invention, it has been found that
30 the amino acid residues Phe, Tyr, Trp, Lys and Arg are particularly sensitive to cleavage by the major proteolytic enzymes in the gastrointestinal tract, i.e. chymotrypsin (cleavage at Phe, Tyr and Trp) and trypsin (cleavage at Lys and Arg). To improve the stability of PAL in the gastrointestinal tract, one or more

of these amino acid residues may therefore be replaced by other residues which are more resistant to proteolytic cleavage.

The parent PAL may be derivable from a microorganism, in particular a fungus such as a Rhodotorula sp., Rhodospiridium sp., Sporobolus sp., Geotrichum sp., Moniliella sp., Pellicularia sp., Gonatobotryum sp., Syncephalastrum sp., Endomyces sp., Aspergillus sp., Saccharomycopsis sp., Eurotium sp., Glomerella sp., Cladosporium sp. or Trichosporon sp., or from a plant such as Pisum sativum, potato, sweet potato or soy bean. A particularly preferred PAL is one derivable from a strain of Rhodospiridium toruloides (syn. Rhodotorula glutinis), or a suitable homologue thereof.

In the present context, the term "homologue" is intended to indicate a PAL of which the amino acid sequence is at least 45% identical to that of the Rhodospiridium toruloides PAL. Sequence comparisons may be performed via known algorithms, such as the one described by Lipman and Pearson, Science 227, 1985, p. 1435. Sequences may be obtained from databases containing Published Sequences. Examples of homologues are PALs derivable from Rhodotorula rubra, Lycopersicon esculentum, Nicotiana tabacum, Ipomoea batatas, Phaseolus vulgaris, Medicago sativa, Petroselinum crispum, Oryza sativa and soybean.

In particular, the protease-stability of PAL may be improved by substituting one or more amino acid residues in the region from amino acid 629 to 674 of the PAL derivable from Rhodospiridium toruloides. Without wishing to be limited to any theory, it is currently assumed that this region forms a loop on the surface of the enzyme, so that the protease-sensitive amino acid residues present in this region are particularly exposed to proteolytic enzymes in the gastrointestinal tract. It is anticipated that amino acid residues in corresponding positions of homologous PALs may likewise be substituted.

More specifically, one or more amino acid residues may be substituted as follows

F629A, S, V, L, E, P, N, I, Q, T, M, G, H, D
F631A, S, V, L, E, P, N, I, Q, T, M, G, H, D
W653A, S, V, L, E, P, N, I, Q, T, M, G, H, D
K654A, S, V, L, E, P, N, I, Q, T, M, G, H, D
5 R667A, S, V, L, E, P, N, I, Q, T, M, G, H, D
R670A, S, V, L, E, P, N, I, Q, T, M, G, H, D
F673A, S, V, L, E, P, N, I, Q, T, M, G, H, D
W674A, S, V, L, E, P, N, I, Q, T, M, G, H, D

Cloning a DNA Sequence Encoding a PAL

10 The DNA sequence encoding a parent PAL may be isolated from any cell or microorganism producing the PAL in question by various methods, well known in the art. Firstly, a genomic DNA and/or cDNA library should be constructed using chromosomal DNA or messenger RNA from the organism that
15 produces the PAL to be studied. Then, if the amino acid sequence of the PAL is known, homologous, labelled oligonucleotide probes may be synthesized and used to identify PAL-encoding clones from a genomic library of bacterial DNA, or from a fungal cDNA library. Alternatively, a labelled oligo-
20 nucleotide probe containing sequences homologous to PAL from another strain of bacteria or fungus could be used as a probe to identify PAL-encoding clones, using hybridization and washing conditions of lower stringency.

Alternatively, the DNA sequence encoding the enzyme
25 may be prepared synthetically by established standard methods, e.g. the phosphoamidite method described by S.L. Beaucage and M.H. Caruthers, Tetrahedron Letters 22, 1981, pp. 1859-1869, or the method described by Matthes et al., The EMBO J. 3, 1984, pp. 801-805. According to the phosphoamidite method, oligo-
30 nucleotides are synthesized, e.g. in an automatic DNA synthesizer, purified, annealed, ligated and cloned in appropriate vectors.

Finally, the DNA sequence may be of mixed genomic and synthetic, mixed synthetic and cDNA or mixed genomic and
35 cDNA origin prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate), the fragments corre-

sponding to various parts of the entire DNA sequence, in accordance with standard techniques. The DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in US 4,683,202 or R.K. 5 Saiki et al., Science 239, 1988, pp. 487-491.

Site-directed Mutagenesis of the PAL-encoding Sequence

Once a PAL-encoding DNA sequence has been isolated, and desirable site for mutation identified, mutations may be introduced using synthetic oligonucleotides. These oligonucleo- 10 tides contain nucleotide sequences flanking the desired mutation sites; mutant nucleotides are inserted during oligonucleotide synthesis. In a specific method, a single-stranded gap of DNA, bridging the PAL-encoding sequence, is created in a vector carrying the PAL gene. Then the synthetic nucleotide, 15 bearing the desired mutation, is annealed to a homologous portion of the single-stranded DNA. The remaining gap is then filled in with DNA polymerase I (Klenow fragment) and the construct is ligated using T4 ligase. A specific example of this method is described in Morinaga et al., (1984, Biotech- 20 nology 2:646-639). U.S. Patent number 4,760,025, by Estell et al., issued July 26, 1988, discloses the introduction of oligonucleotides encoding multiple mutations by performing minor alterations of the cassette, however, an even greater variety of mutations can be introduced at any one time by the 25 Morinaga method, because a multitude of oligonucleotides, of various lengths, can be introduced.

Another method of introducing mutations into PAL-encoding sequences is described in Nelson and Long, Analytical Biochemistry 180, 1989, pp. 147-151. It involves the 3-step 30 generation of a PCR fragment containing the desired mutation introduced by using a chemically synthesized DNA strand as one of the primers in the PCR reactions. From the PCR-generated fragment, a DNA fragment carrying the mutation may be isolated by cleavage with restriction endonucleases and reinserted into 35 the plasmid.

Expression of PAL Variants

According to the invention, a mutated PAL-encoding sequence produced by methods described above, or any alternative methods known in the art, may be expressed using an expression vector which typically includes control sequences encoding a promoter, operator, ribosome binding site, translation initiation signal, and, optionally, a repressor gene or various activator genes. To permit secretion of the expressed protein, nucleotides encoding a "signal sequence" may be inserted prior to the PAL-coding sequence. For expression under the direction of control sequences, a target gene to be treated according to the invention is operably linked to the control sequences in the proper reading frame. Promoter sequences that can be incorporated into plasmid vectors, and which can support the transcription of the mutant PAL gene, include but are not limited to the prokaryotic β -lactamase promoter (Villa-Kamaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731) and the tac promoter (DeBoer, et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25). Further references can also be found in "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94.

According to one embodiment B. subtilis is transformed by an expression vector carrying the mutated DNA. If expression is to take place in a secreting microorganism such as B. subtilis a signal sequence may follow the translation initiation signal and precede the DNA sequence of interest. The signal sequence acts to transport the expression product to the cell wall where it is cleaved from the product upon secretion. The term "control sequences" as defined above is intended to include a signal sequence, when present.

In a currently preferred method, the PAL or PAL variants may be produced in a yeast host cell expressing a DNA sequence encoding the enzyme. Examples of preferred yeast hosts are Saccharomyces, e.g. Saccharomyces cerevisiae or Saccharomyces kluyveri, Schizosaccharomyces, e.g. Schizosaccharomyces pombe, Kluyveromyces, e.g. Kluyveromyces lactis, Pichia, e.g. Pichia pastoris, or Yarrowia, e.g. Yarrowia lipolytica. The PAL

may also be produced in Rhodospiridium toruloides from which the gene is preferentially derived.

The DNA sequence encoding PAL may, for instance, be isolated as described in GB 2 213 486. As the amino acid sequence of PAL is known, it may also be possible to construct a synthetic gene encoding the enzyme.

The intracellular expression of PAL may be achieved by linking the PAL-encoding DNA sequence to a suitable control system such as a promoter, ribosome-binding sequences and terminator sequence. Suitable promoters for use in yeast host cells include promoters from yeast glycolytic genes (Hitzeman et al., J. Biol. Chem. 255, 1980, pp. 12073-12080; Alber and Kawasaki, J. Mol. Appl. Gen. 1, 1982, pp. 419-434) or alcohol dehydrogenase genes (Young et al., in Genetic Engineering of Microorganisms for Chemicals (Hollaender et al, eds.), Plenum Press, New York, 1982), or the TPI1 (US 4, 599, 311) or ADH2-4c (Russell et al., Nature 304, 1983, pp. 652-654) promoters.

The procedures used to ligate the DNA sequences coding for the PAL, the promoter and the terminator, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989).

To provide extracellular production of PAL into the culture medium, the control system may include a suitable signal sequence, such as the MF α signal/leader sequence (Kurjan and Herskowitz, Cell, 1982, pp. 933-943). Examples of other signal/leader sequences are described in WO 89/02463 and WO 92/11378.

Transformation of the yeast cells with a vector containing the PAL gene and expression thereof may be carried out according to well-known procedures, e.g. as described in WO 90/10075.

In another method of producing PAL or PAL variants of the invention, a filamentous fungus is used as the host organism. The filamentous fungus host organism may conveniently

be one which has previously been used as a host for producing recombinant proteins, e.g. a strain of Aspergillus sp., such as A. niger, A. nidulans or A. oryzae. The use of A. oryzae in the production of recombinant proteins is extensively described in, 5 e.g. EP 238 023.

For expression of PAL variants in Aspergillus, the DNA sequence coding for the PAL variant is preceded by a promoter. The promoter may be any DNA sequence exhibiting a strong transcriptional activity in Aspergillus and may be 10 derived from a gene encoding an extracellular or intracellular protein such as an amylase, a glucoamylase, a protease, a lipase or a glycolytic enzyme.

Examples of suitable promoters are those derived from the gene encoding A. oryzae TAKA amylase, Rhizomucor 15 miehei aspartic proteinase, A. niger neutral α -amylase, A. niger acid stable α -amylase, A. niger glucoamylase, Rhizomucor miehei lipase, A. oryzae alkaline protease or A. oryzae triose phosphate isomerase.

In particular when the host organism is A. oryzae, 20 a preferred promoter for use in the process of the present invention is the A. oryzae TAKA amylase promoter as it exhibits a strong transcriptional activity in A. oryzae. The sequence of the TAKA amylase promoter appears from EP 238 023.

Termination and polyadenylation sequences may 25 suitably be derived from the same sources as the promoter.

The techniques used to transform a fungal host cell may suitably be as described in EP 238 023.

To ensure secretion of the PAL variant from the host cell, the DNA sequence encoding the PAL variant may be 30 preceded by a signal sequence which may be a naturally occurring signal sequence or a functional part thereof or a synthetic sequence providing secretion of the protein from the cell. In particular, the signal sequence may be derived from a gene encoding an Aspergillus sp. amylase or glucoamylase, a 35 gene encoding a Rhizomucor miehei lipase or protease, or a gene encoding a Humicola cellulase, xylanase or lipase. The signal sequence is preferably derived from the gene encoding A. oryzae

TAKA amylase, A. niger neutral α -amylase, A. niger acid-stable α -amylase or A. niger glucoamylase.

The medium used to culture the transformed host cells may be any conventional medium suitable for growing 5 Aspergillus cells. The transformants are usually stable and may be cultured in the absence of selection pressure. However, if the transformants are found to be unstable, a selection marker introduced into the cells may be used for selection.

The mature PAL protein may conveniently be 10 recovered from the culture by well-known procedures including lysing the cells and precipitating proteinaceous components of the medium by means of a salt such as ammonium sulphate, followed by chromatographic procedures such as ion exchange chromatography, affinity chromatography, or the like.

15 The present invention also relates to a pharmaceutical composition containing the enzyme preparation or PAL variant of the invention together with a pharmaceutically acceptable carrier or excipient. In the composition of the invention, the enzyme may be formulated by any one of the 20 established methods of formulating pharmaceutical compositions, e.g. as described in Remington's Pharmaceutical Sciences, 1985. The composition should be in a form adapted for oral administration, including a powder, granulate, tablet, capsules, microcapsule, solution or suspension. Suitable carriers and 25 excipients for oral administration are well known in the art.

The pharmaceutical composition of the invention is suitably provided in unit dosage form such as a tablet or capsule. To protect the enzyme from degradation by gastric fluid, such tablets or capsules are preferably provided with an 30 enteric coating, that is, a coating which is insoluble at gastric pH but dissolves at intestinal pH (typically at a pH of 5 or more). Examples of suitable enteric coating agents are cellulose acetate phthalate (CAP, Cellacephate®), vinyl acetate crotonic acid copolymer (Luviset®), methacrylic acid, (meth)acrylic acid ester copolymer (Eudragit®) or hydroxypropyl 35 methylcellulose phthalate. For a further description of enteric coatings and coating processes, reference is made to WO

87/07292. Another suitable pharmaceutical composition is a controlled release formulation from which the enzyme is released during its passage through the gastrointestinal tract.

The composition of the invention may be used for the prevention or treatment of hyperphenylalaninemia, in particular phenylketonuria, as previously suggested by i.a. J.A. Hoskins et al., Lancet, February 23, 1980, pp. 392-394; H.J. Gilbert and M. Tully, Biochem. Biophys. Res. Comm. 131(2), 1985, pp. 557-563; and L. Bourget and T.M.S. Chang, Biochim. Biophys. Acta 883, 1986, pp. 432-438. A suitable dose of PAL to keep the plasma phenylalanine level below the critical level is in the range of from about 50 to about 500 mg PAL protein per day, in particular about 200 mg PAL protein per day.

The invention is described in further detail in the following examples which are not in any way intended to limit the scope of the invention as claimed.

Example 1

Cultivation of PAL Producing Cells

Four strains: Rhodotorula graminis (ATCC 20804), Rhodotorula minuta (NRRL Y-1589), Rhodospiridium toruloides (NRRL Y-1091), and Rhodotorula aurantiaca (NRRL Y-7219) were cultured in shake flasks at the following conditions:

Medium: 2% yeast extract, 2% peptone, 0.4% phenylalanine, and 6% glucose

Culture: 26 °C, 250 rpm, 4 days

PAL activity was analysed on supernatants after homogenization of culture broth with 1 g of glass beads pr. ml.

Permeabilisation and Immobilisation of Cells by Glutaraldehyde Modification

Cells were diluted with water to reduce viscosity and adjusted to pH 8. They were then frozen at -20 °C in ethanol/dry ice and thawed for permeabilisation. During ice

bath cooling, glutaraldehyde was added to a final concentration of 0.5%. pH was readjusted to 8 and stirring continued for 1 hour. The cells were centrifuged for 10 minutes at 7000 rpm. This was repeated after decantation and suspension in 20 ml water followed by freeze-drying of the cells. Details regarding the three cell batches are given below:

Strain/batch	ATCC 20804	NRRL Y-1589	ATCC 20804
Cell activity	-	-	6.6 U/ml*
Cell volume used	11 ml	16 ml	9.3 g
Added water	9 ml	2 ml	8.2 g
pH	5.6	6.2	5.7
4N NaOH → pH 8	400 µl	400 µl	200 µl
Glutaraldehyde, 50%	200 µl	180 µl	177 µl
Immobilized PAL	1.13 g	2.15 g	0.94 g
Activity	0.57 U/g	1.96 U/g	11.3 U/g

(#) Immobilization: 2 hours at room temperature. Vacuum drying overnight at 40°C. Ground in mortar.

(*) Approx. activity based on concentrated culture broth.

Comparison Preparations

Acetone permeabilised cells were made basically as described by Gilbert and Tully. The cells were diluted with water and adjusted to pH 8 as for the glutaraldehyde treated cells. They were then added dropwise to 20 volumes of -10°C acetone (made with dry ice). After standing 15 minutes under occasional stirring, they were allowed to settle for 5-10 minutes. After filtering and re-suspension in 200 ml cold water, cells were collected by centrifugation, 7000 rpm for 12 minutes, followed by freeze-drying. Details for the two batches are given below:

Strain/batch	NRRL Y-1091	NRRL Y-7219
Cell volume used	13 ml	18 ml
Added water	8 ml	7 ml
pH	7.2	7.7
5 4N NaOH → pH 8	100 µl	100 µl
Acetone	200 ml	240 ml
Dry cell yield	0.32 g	0.44 g
Activity	1.23 U/g	1.79 U/g

Activity and Stability Analyses

10 PAL activity was determined in principle by the measurement of cinnamate at 290 nm from 13 mM phenylalanine, 0.1 M Tris, pH 8.5, 37°C described by Gilbert and Jack. A linear relation between cinnamate concentration and OD₂₉₀ allows calculation of PAL activity in units of µmoles cinnamate/-
 15 minute. In order to assay the immobilized preparations, incubation of samples was followed by separation of immobilized PAL before measurement at 290 nm.

Stability towards chymotrypsin with subsequent assay of residual PAL activity was analyzed as follows:

20 Chymotrypsin (Novo Nordisk, 1000 USP/mg, < 25 USP/mg trypsin) was added to the 13 mM phenylalanine substrate (0.1 M Tris, pH 8.5) in concentrations of 0, 3, 30, and 300 USP/ml. 25 mg immobilized PAL was added to 10 ml substrate, preheated to 37°C, and shaken at 37°C (vertically in 20 ml
 25 glass tubes). 3.0 ml samples were taken at 5 and 30 minutes and filtered before OD₂₉₀ measurement. Reference: Substrate with chymotrypsin. Blank samples: Tris-buffer without phenylalanine, with chymotrypsin, and with immobilized PAL. Reference to blank samples: Chymotrypsin in Tris-buffer.

30 Activity calculation:

$$\text{Activity in U/g} = \epsilon * l * v * [(E_{30} - E_{308}) - (E_5 - E_{58})] / t * m$$

ϵ = molar extinction coefficient of cinnamate: $1 \cdot 10^4$ liter/-
mole/cm
l = cuvette width: 1 cm
v = substrate volume: 10 ml
5 t = reaction time: 25 minutes
m = amount of enzyme: 25 mg
E₃₀ = extinction of sample at 30 minutes
E_{30B} = extinction of blank at 30 minutes
E₅ = extinction of sample at 5 minutes
10 E_{5B} = extinction of blank at 5 minutes

With these values, $A = 1.60 \cdot [(E_{30} - E_{30B}) - (E_5 - E_{5B})]$, in U/g

Soluble PAL (Sigma P-1016, lot 22H8000, from Rhodotorula glutinis) was analysed to 2.8 U/ml and diluted 1:10 prior to incubation with 2.6 USP/ml chymotrypsin (batch as 15 above) in 0.1 M Tris, pH 7.5, 37°C. Residual PAL activity was assayed after 15 and 30 minutes and calculated relative to original activity.

Results:

Immobilized preparation	Residual activity, U/g and %, at different chymotrypsin levels			
	0 USP/ml	3 USP/ml	30 USP/ml	300 USP/ml
5 Glutaraldehyde treated ATCC 20804100	0.57 100	0.53 93	0.53 93	0.44 77
Glutaraldehyde treated	1.96 100	1.69 86	1.76 90	1.34 68
10 NRRL Y-1589				
Glutaraldehyde treated ATCC 20804	11.3 100	- -	- -	11.3 100
Comparisons				
15 preparations				
Acetone permeabilized NRRL Y-1091	1.23 100	0.89 72	0.55 45	0.28 23
20 Acetone permeabilized NRRL Y-7219	1.79 100	1.11 62	0.90 50	0.54 30
Soluble PAL	2.8 U/ml 100%	0.02 U/ml 0.8% (2.5% after 15 minutes)		
25				

These results demonstrate the efficiency of glutaraldehyde treatment in stabilizing PAL-containing Rhodotorula cells towards chymotrypsin.

CLAIMS

1. An enzyme preparation comprising phenylalanine ammonia lyase (PAL) stabilised against proteolytic degradation by chemical or genetic modification.
- 5 2. An enzyme preparation according to claim 1 wherein the enzyme is stabilised by treatment with a cross-linking agent.
3. An enzyme preparation according to claim 2 which includes whole cells containing PAL, permeabilised cells
10 containing PAL, a cell homogenate containing PAL or cell-free PAL.
4. An enzyme preparation according to claim 3, wherein PAL constitutes at least 25%, preferably at least 50%, of the enzyme protein in the preparation.
- 15 5. An enzyme preparation according to claim 3, wherein the PAL is in crystalline form.
6. An enzyme preparation according to claim 2, wherein the cross-linking agent is a bifunctional reagent.
7. An enzyme preparation according to claim 6,
20 wherein the cross-linking agent is selected from the group consisting of pharmaceutically acceptable carbodiimides, isoxazolium derivatives, chloroformates, carbonyldiimidazole, bis-imidoesters, bis-succinimidyl derivatives, di-isocyanates, di-isothiocyanates, di-sulfonyl halides, bis-nitrophenyl
25 esters, dialdehydes, diacylazides, bis-maleimides, bis-haloacetyl derivatives, di-alkyl halides and bis-oxiranes.
8. An enzyme preparation according to claim 7, wherein the dialdehyde is glutaraldehyde.

9. An enzyme preparation according to any of claims 1-8, wherein the PAL is derivable from a microorganism, in particular a fungus such as a Rhodotorula sp., Rhodosporidium sp., Sporobolus sp., Geotrichum sp., Moniliella sp., Pellicularia sp., Gonatobotryum sp., Syncephalastrum sp., Endomyces sp., Aspergillus sp., Saccharomycopsis sp., Eurotium sp., Glomerella sp., Cladosporium sp. or Trichosporon sp., or a plant such as Pisum sativum, potato, sweet potato or soy bean.

10. A PAL variant stabilised against proteolytic degradation, wherein one or more amino acid residues susceptible to proteolytic cleavage are substituted by one or more amino acid residues less susceptible to proteolytic cleavage.

11. A PAL variant according to claim 10, wherein one or more of the amino acid residues Phe, Tyr, Trp, Lys or Arg are substituted by one or more other amino acid residues.

12. A PAL variant according to claim 10 or 11, wherein the parent PAL is derived from a microorganism, in particular a fungus such as a Rhodotorula sp., Rhodosporidium sp., Sporobolus sp., Geotrichum sp., Moniliella sp., Pellicularia sp., Gonatobotryum sp., Syncephalastrum sp., Endomyces sp., Aspergillus sp., Saccharomycopsis sp., Eurotium sp., Glomerella sp., Cladosporium sp. or Trichosporon sp., or a plant such as Pisum sativum, potato, sweet potato or soy bean.

13. A PAL variant according to claim 12, wherein the parent PAL is derived from Rhodosporidium toruloides.

14. A PAL variant according to claim 13, wherein one or more amino acid residues are substituted in the region from amino acid 629 to 674.

15. A PAL variant according to claim 14, wherein one or more amino acid residues are substituted as follows

F629A, S, V, L, E, P, N, I, Q, T, M, G, H, D
F631A, S, V, L, E, P, N, I, Q, T, M, G, H, D
W653A, S, V, L, E, P, N, I, Q, T, M, G, H, D
K654A, S, V, L, E, P, N, I, Q, T, M, G, H, D
5 R667A, S, V, L, E, P, N, I, Q, T, M, G, H, D
R670A, S, V, L, E, P, N, I, Q, T, M, G, H, D
F673A, S, V, L, E, P, N, I, Q, T, M, G, H, D
W674A, S, V, L, E, P, N, I, Q, T, M, G, H, D

16. A DNA construct comprising a DNA sequence
10 encoding a PAL variant according to any of claims 10-15.

17. A recombinant expression vector comprising a
DNA construct according to claim 16.

18. A cell transformed with a DNA construct
according to claim 16 or a recombinant expression vector
15 according to claim 17.

19. A cell according to claim 18, which is a
microbial cell, in particular a yeast cell such as a cell of
Rhodotorula glutinis, Saccharomyces, e.g. Saccharomyces
cerevisiae or Saccharomyces kluyveri, Schizosaccharomyces, e.g.
20 Schizosaccharomyces pombe, Kluyveromyces, e.g. Kluyveromyces
lactis, Pichia, e.g. Pichia pastoris, or Yarrowia, e.g.
Yarrowia lipolytica, or a filamentous fungal cell such as a
cell of Aspergillus, e.g. Aspergillus niger, Aspergillus oryzae
or Aspergillus nidulans, or Trichoderma, e.g. Trichoderma
25 reesei.

20. A process for preparing a PAL variant according
to any of claims 10-15, the process comprising culturing a cell
according to claim 18 in a suitable culture medium under
conditions permitting production of the PAL variant, and
30 recovering the resulting PAL variant from the culture.

21. A pharmaceutical composition adapted for oral administration and comprising an enzyme preparation according to any of claims 1-9 or a PAL variant according to any of claims 10-15 together with a pharmaceutically acceptable carrier or excipient.

22. A pharmaceutical composition for the prevention or treatment of hyperphenylalaninemia and comprising an enzyme preparation according to any of claims 1-9 or a PAL variant according to any of claims 10-15 together with a pharmaceutically acceptable carrier or excipient.

23. A composition according to claim 21 or 22 in the form of a tablet or capsule provided with an enteric coating.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 94/00224

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁵: A61K 37/56, C12N 11/00, C12N 9/88 // C12N 9/96

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁵: C12N, A61K, C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Chemical Abstracts, Volume 92, No 1, 7 January 1980 (07.01.80), (Columbus, Ohio, USA), Wieder, Kenneth J. et al, "Some properties of polyethylene glycol: phenylalanine ammonia-lyase adducts", page 2445, THE ABSTRACT No 2439y, J. Biol. Chem. 1979, 254 (24), 12579-12587	1-9
Y	--	21-23
X	Chemical Abstracts, Volume 94, No 7, 16 February 1981 (16.02.81), (Columbus, Ohio, USA), Davis, F. F. et al, "Soluble, nonantigenic polyethylene glycol-bound enzymes", page 226, THE ABSTRACT No 43310j, Polym. Prepr., Am. Chem. Soc. 1979, 20 (1), 357-360	1-9,21-23
	--	

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"B" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

30 Sept 1994

Date of mailing of the international search report

07 -10- 1994

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Carl Olof Gustafsson

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 94/00224

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 4762707 (FRANZ JANSEN), 9 August 1988 (09.08.88), claims 1 and 15 --	1
Y	DE, A1, 2919127 (SNAMPROGETTI S.P.A.), 22 November 1979 (22.11.79), see page 6-page 7, first paragraph --	1-9,21-23
Y	National Library of Medicine, NLM, accession no. 89375668, Bourget L: "Effects of oral admini- stration of artificial cells immobilized pheny- lalanine ammonia-lyase on intestinal amino acids of phenylketonuric rats", & Biomater Artif Cells Artif Organs 1989;17(2):161-81 --	1-9,21-23
A	National Library of Medicine, NML, accession no. 87000699, Bourget L: "Phenylalanine ammonia- lyase immobilized in microcapsules for the depletion of phenylalanine in plasma in phenyl- ketonuric rat model", Biochim Biophys Acta 1986 Oct 1;883(3):432-8 --	1-23
A	Patent Abstracts of Japan, Vol 9, No 324, C-320, abstract of JP, A, 60-155125 (KANEBO K.K.), 15 August 1985 (15.08.85) --	1-9
A	Chemical Abstracts, Volume 89, No 23, 4 December 1978 (04.12.78), (Columbus, Ohio, USA), Ambrus, Clara M et al, "Phenylalanine depletion for the management of phenylketonuria: use of enzyme reactors with immobilized enzymes", page 53, THE ABSTRACT No 191071u, Science 1978, 4358, 837-839 --	1
Y	US, A, 4970156 (STATIS AVRAMEAS ET AL), 13 November 1990 (13.11.90), see table I --	1-9,21-23

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 94/00224

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>National Library of Medicine, NLM, accession no. 86025495, Gilbert HJ: "Protection of phenylalanine ammonia-lyase from proteolytic attack", & Biochem Biophys Res Commun 1985 Sep 16;131(2):557-63</p> <p style="text-align: center;">--</p>	1-23
A	<p>National Library of Medicine, NLM, accession no. 87100106, Inoue S: "Entrapment of phenylalanine ammonia-lyase in silk fibroin for protection from proteolytic attack", Biochem Biophys Res Commun 1986 Nov 26;141(1):165-70</p> <p style="text-align: center;">-- -----</p>	1-23

INTERNATIONAL SEARCH REPORT
Information on patent family members

27/08/94

International application No.

PCT/DK 94/00224

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A- 4762707	09/08/88	AU-B- 563356	09/07/87
		AU-A- 1250483	22/09/83
		EP-A,B- 0089880	28/09/83
		SE-T3- 0089880	
		FR-A,B- 2523445	23/09/83
		JP-A- 58208238	03/12/83
		OA-A- 7388	30/11/84
DE-A1- 2919127	22/11/79	AU-B- 521742	29/04/82
		AU-A- 4689579	15/11/79
		BE-A- 876204	12/11/79
		CA-A- 1130206	24/08/82
		FR-A,B- 2425246	07/12/79
		FR-A,B- 2441705	13/06/80
		GB-A,B- 2020668	21/11/79
		JP-A- 54147909	19/11/79
		LU-A- 81242	10/09/79
		NL-A- 7903789	14/11/79
		SE-A- 7904161	13/11/79
		US-A- 4235087	25/11/80
		US-A- 4248704	03/02/81
US-A- 4970156	13/11/90	CA-A- 953214	20/08/74
		CH-A- 538003	31/07/73
		CH-A- 564031	15/07/75
		DE-A,B,C 1915970	09/10/69
		FR-A- 1604982	26/06/72
		FR-A,B- 2107801	12/05/72
		GB-A- 1257263	15/12/71
		US-A- 4004979	25/01/77
		US-A- 4464468	07/08/84
		FR-A- 2028702	16/10/70
		FR-A,B- 2035774	24/12/70